Latest Resolve Therapeutics LLC Stories
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE). http://photos.prnewswire.com/prnvar/20140715/127341 Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients. The...
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with its lead compound RSLV-132. Resolve administered the first doses to humans of RSLV-132 its first-in-class targeted nuclease therapy designed to decrease the burden of circulating RNA-containing immune complexes in SLE patients. Ongoing studies are designed to evaluate the safety, tolerability,...
- Remarkable; prodigious.
- Audacious; gutsy.
- Completely; extremely.
- Audaciously; boldly.
- Impressively great in size; enormous; extraordinary.